GlassScriptPhysician profile
Christin Noel Demoss
NPI 1902336043
$878.13
in general payments reported to CMS, 2019-2025
14 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2021: $34.45 · 2022: $176 · 2023: $129 · 2024: $92.14 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $195.17 | 2019-2025 | Tryptyr |
| Spark Therapeutics, INC. | $125.01 | 2022 | |
| Sun Pharmaceutical Industries INC. | $120.65 | 2021-2023 | Cequa |
| Shire North American Group INC | $106.68 | 2019 | |
| Genzyme Corporation | $56.28 | 2022-2025 | |
| Samsara Vision | $42.54 | 2023 | |
| Glaukos Corporation | $40.91 | 2024 | Radius |
| Bausch & Lomb Americas INC. | $39.85 | 2025 | Vyzulta |
| Allergan, INC. | $39.60 | 2019-2022 | |
| Abbvie INC. | $27.11 | 2024 | |
| Harrow Eye, LLC | $25.50 | 2025 | Vevye |
| Dompe US, INC. | $24.12 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $18.10 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christin Demoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.